Annals of Oncology Advance Access published online on December 20, 2007
Annals of Oncology, doi:10.1093/annonc/mdm568
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org
letter to the editor |
Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial
| The first 10% of the full text of this article appears below. |
After the seminal observations of Huggins and Hodges [1] had laid the basis for the hormonal therapy of prostate cancer, Pearson [2] described two patients with castration-resistant prostate cancer that responded to testosterone with relief of symptoms and declines in serum acid phosphatase. The particular molecular context for this seeming paradox
Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, 1155 Herman P. Pressler, Houston, TX 77030-3721, USA
(E-mail: pmathew@mdanderson.org)